Drug firm Sun Pharma today said it has received tentative approval from US health regulator to sell a generic version of Rilutek tablets, used in treating central nervous system diseases, in the American market.
The Mumbai-based firm has received a tentative approval for Abbreviated New Drug Application (ANDA) for a generic version of Rilutek tablets in 50 mg strength, Sun Pharmaceutical Industries said in a statement.
Rilutek tablets, a Sanofi Aventis product, has annual sales of nearly $50 million in the United States. The generic version of the tablets contain Riluzole Hydrochloride in the strength of 50 mg, it said.
Riluzole Hydrochloride tablets are indicated in the treatment of amyotrophic lateral sclerosis (ALS). ALS is a disease of the central nervous system that affects a person's ability to move certain muscles.
Shares of Sun Pharma today closed at Rs 1968.50 on Bombay Stock Exchange, up 1.07 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app